By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cara Therapeutics, Inc. 

One Parrott Drive

Shelton  Connecticut  06484  U.S.A.
Phone: 203-567-1500 Fax: 203-567-1510


Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated activity in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was observed to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara recently initiated its Phase 3 program with I.V. CR845 in postoperative pain. Cara also has an ongoing Phase 2 trial of an oral tablet formulation of CR845, for the treatment of osteoarthritis (OA).

Key Statistics

Ownership: Public

Web Site: Cara Therapeutics
Symbol: CARA

Company News
Cara Therapeutics (CARA) Reports Continuation Of Phase III Trial Of I.V. CR845 In Postoperative Pain Following Interim Assessment 6/21/2017 7:38:44 AM
Cara Therapeutics (CARA): A Look At The Next Catalyst—Osteoarthritis 5/16/2017 7:20:45 AM
Cara Therapeutics (CARA) Reports First Quarter 2017 Financial Results 5/5/2017 11:26:03 AM
Cara Therapeutics (CARA) To Announce First Quarter 2017 Financial Results On May 4, 2017 4/27/2017 11:11:26 AM
Cara Therapeutics (CARA) Announces Positive Data From Quantitative Phase I Trial Measuring Respiratory Safety Of I.V. CR845 4/24/2017 11:29:05 AM
What Makes Cara Therapeutics (CARA) So Intriguing? 3/17/2017 6:13:39 AM
Enteris Biopharma's "Feasibility To Licensing" Partner, Cara Therapeutics (CARA), Advances Peptelligence-Engineered CR845 Into Phase 2b Clinical Trial In Chronic Pain 9/19/2016 7:29:27 AM
FDA Removes Clinical Hold on Cara Therapeutics (CARA)'s Phase III Postoperative Pain Study 4/20/2016 6:13:31 AM
Cara Therapeutics (CARA) Crashes as the FDA Places Clinical Hold on Late-Stage Pain Drug Trial 2/26/2016 6:56:28 AM
Cara Therapeutics (CARA) Announces Positive Top-Line Results From Phase IIa Trial Of Oral CR845 In Chronic Pain Patients With Osteoarthritis Of The Knee Or Hip 12/9/2015 7:23:32 AM